Viracta Therapeutics (VIRX)
(Delayed Data from NSDQ)
$0.22 USD
0.00 (-0.27%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $0.22 0.00 (-1.70%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Viracta Therapeutics, Inc. [VIRX]
Reports for Purchase
Showing records 1 - 20 ( 22 total )
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Topline Stage 1 NAVAL-1 Results in R/R EBV+ PTCL are Consistent With Prior Releases
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Several Datasets Expected in 2024; 2023 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Projected 2024 Catalysts Announced; Lowering PT to $4
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Datasets in 2024; 3Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
First Expansion Cohort For NAVAL-1 Trial Announced; Lowering PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Key Updates Expected in 2023; 1Q23 Financial Results; Modulating PT to $33
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Key Updates Expected This Year; 2022 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initial EBV+ Solid Tumor Results Next Month; 3Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Key 4Q22 Developments; 2Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initial Phase 1 EBV+ Solid Tumor Results Expected in 2H22; 1Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Dosed in Phase 1b/2 EBV+ Solid Tumor Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Datasets Slated for ASH; 3Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Phase 1 Trial in EBV+ Solid Tumors Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Board Member Additions; 2Q21 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Phase 1 Combo Trial in EBV+ Solid Tumors Starting in 2H21; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
NAVAL-1 Pivotal Trial Initiation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R